申请人:Wei T. Edward
公开号:US20070053834A1
公开(公告)日:2007-03-08
One embodiment of the invention is a composition that comprises a radioactive [
18
F], [
76
Br]-, [
77
Br]-, [
211
At]-, [
123
I], [
125
I], or [
131
I]-N-radioistope-labeled-aryl-alkyl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer cells. The [
18
F], [
76
Br]-, [
77
Br]-, [
211
At]-, [
123
I], [
125
I], or [
131
I]-N-radioistope-labeled-aryl-alkyl-alkylcarboxamide ligand may be used for radioreceptor binding studies, for diagnostic studies, and for radiotherapy of cancerous tissues. Affinity of the N-radioistope-labeled-aryl-alkyl-alkylcarboxamide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells.
本发明的一个实施例是一种组合物,该组合物包括放射性[18F]、[76Br]、[77Br]、[211At]、[123I]、[125I]或[131I] -N-放射性同位素标记的芳基-烷基-烷基羧酰胺分子。该组合物能够结合到细胞的瞬时受体电位-M8(TRP-M8)受体上。TRP-M8受体在感觉神经元和恶性组织(如前列腺癌细胞)中有选择性表达。[18F]、[76Br]、[77Br]、[211At]、[123I]、[125I]或[131I]-N-放射性同位素标记的芳基-烷基-烷基羧酰胺配体可用于放射受体结合研究、诊断研究和癌症组织放射治疗。N-放射性同位素标记的芳基-烷基-烷基羧酰胺配体对TRP-M8受体的亲和力赋予了选择性和特异性,可将致命辐射传递到患病细胞。